RedHill Biopharma (RDHL) Tops Q2 Loss Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. QGEN
5. QS
6. BFH
7. BRO
8. SAP
9. RCUS
10. LMT

Go back to RedHill Biopharma (RDHL) Tops Q2 Loss Views

RedHill Biopharma Reports Results for the Second Quarter of 2015

July 29, 2015 6:05 AM EDT

Key Highlights Include:

Strong cash position of approximately $26.6 million at the end of the second quarter of 2015 and approximately $66 million as of July 28, 2015, following the Company's July 2015 public offering in the U.S. Gross proceeds of $44.5 million from the Company's July 2015 public offering in the U.S., including the exercise of 277,143 ADSs by the underwriters under their over-allotment option; Participants in the public offering included prominent U.S. healthcare institutional investors RedHill's partner, Salix Pharmaceuticals, confirmed that it continues the development of RedHill's RHB-106 solid oral bowel... More